Monitoring while on Wegovy Your healthcare team should monitor your kidney function more closely when you start Wegovy
Tirzepatide produced 20.2% weight loss compared to 13.7% for semaglutide at 72 weeks
Results Cohort Derivation and Baseline Characteristics Figure 2 shows a flow diagram of participant screening, exclusions, and final cohort numbers
Cardiovascular disease (CVD) is the main cause of death and disability among people with type 2 diabetes.[2] Adults with type 2 diabetes are two to four times more likely to develop CVD than adults without diabetes.[3] The FDA's decision on semaglutide is based on results from the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which examined the cardiovascular safety of adding Ozempic or placebo to standard-of-care in adults with type 2 diabetes and established cardiovascular disease
Only male mice were used in this study to minimize variability associated with the estrous cycle and because male db/db mice exhibit more severe and consistent hyperglycemia
But those changes arent directly connected to these medications, or any specific weight loss medication, explains obesity medicine subspecialist W
